loadpatents
name:-0.032317876815796
name:-0.017307043075562
name:-0.014058113098145
EKSTEROWICZ; John Patent Filings

EKSTEROWICZ; John

Patent Applications and Registrations

Patent applications and USPTO patent grants for EKSTEROWICZ; John.The latest application filed is for "cd73 inhibitors".

Company Profile
15.19.31
  • EKSTEROWICZ; John - Burlingame CA
  • Eksterowicz; John - San Francisco CA
  • EKSTEROWICZ; John - South San Francisco CA
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Cd73 Inhibitors
App 20220259253 - DU; Xiaohui ;   et al.
2022-08-18
Cd73 Inhibitors
App 20220220147 - DU; Xiaohui ;   et al.
2022-07-14
CD73 inhibitors
Grant 11,377,469 - Du , et al. July 5, 2
2022-07-05
Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
App 20220169611 - Bartberger; Michael D. ;   et al.
2022-06-02
CD73 inhibitors
Grant 11,325,938 - Du , et al. May 10, 2
2022-05-10
Glucocorticoid Receptor Modulators
App 20220079924 - DU; Xiaohui ;   et al.
2022-03-17
Cd73 Inhibitors
App 20220054512 - DU; Xiaohui ;   et al.
2022-02-24
Inhibitors of glucocorticoid receptor
Grant 11,208,432 - Sun , et al. December 28, 2
2021-12-28
Inhibitors Of Glucocorticoid Receptor
App 20210395295 - SUN; Daqing ;   et al.
2021-12-23
Inhibitors Of Glucocorticoid Receptor
App 20210379084 - SUN; Daqing ;   et al.
2021-12-09
CD73 inhibitors
Grant 11,129,841 - Du , et al. September 28, 2
2021-09-28
CD73 inhibitors
Grant 11,130,778 - Du , et al. September 28, 2
2021-09-28
Inhibitors of glucocorticoid receptor
Grant 11,124,537 - Sun , et al. September 21, 2
2021-09-21
Inhibitors of glucocorticoid receptor
Grant 11,110,103 - Sun , et al. September 7, 2
2021-09-07
Cd73 Inhibitors
App 20210214387 - DU; Xiaohui ;   et al.
2021-07-15
Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
App 20210179560 - Bartberger; Michael D. ;   et al.
2021-06-17
CD73 inhibitors
Grant 11,028,120 - Du , et al. June 8, 2
2021-06-08
Cd73 Inhibitors
App 20210130389 - DU; Xiaohui ;   et al.
2021-05-06
Cd73 Inhibitors
App 20210130390 - DU; Xiaohui ;   et al.
2021-05-06
Glucocorticoid Receptor Modulators
App 20210122730 - DU; Xiaohui ;   et al.
2021-04-29
Cd73 Inhibitors
App 20210047359 - Du; Xiaohui ;   et al.
2021-02-18
Inhibitors Of Glucocorticoid Receptor
App 20210023095 - SUN; Daqing ;   et al.
2021-01-28
Inhibitors Of Glucocorticoid Receptor
App 20210017219 - SUN; Daqing ;   et al.
2021-01-21
Inhibitors Of Glucocorticoid Receptor
App 20210017220 - SUN; Daqing ;   et al.
2021-01-21
Inhibitors Of Glucocorticoid Receptor
App 20210002324 - SUN; Daqing ;   et al.
2021-01-07
Inhibitors of glucocorticoid receptor
Grant 10,836,789 - Sun , et al. November 17, 2
2020-11-17
Cd73 Inhibitors
App 20200347090 - DU; Xiaohui ;   et al.
2020-11-05
Inhibitors Of Glucocorticoid Receptor
App 20200291058 - SUN; Daqing ;   et al.
2020-09-17
Inhibitors of glucocorticoid receptor
Grant 10,723,759 - Sun , et al.
2020-07-28
Cd73 Inhibitors
App 20200093844 - DU; Xiaohui ;   et al.
2020-03-26
Inhibitors Of Glucocorticoid Receptor
App 20200055892 - SUN; Daqing ;   et al.
2020-02-20
Inhibitors of glucocorticoid receptor
Grant 10,472,387 - Sun , et al. Nov
2019-11-12
Inhibitors Of Glucocorticoid Receptor
App 20190218246 - SUN; Daqing ;   et al.
2019-07-18
Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
App 20190062276 - Bartberger; Michael D. ;   et al.
2019-02-28
Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
App 20170144971 - BARTBERGER; Michael D. ;   et al.
2017-05-25
Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer
Grant 9,593,129 - Bartberger , et al. March 14, 2
2017-03-14
Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
Grant 9,376,425 - Bartberger , et al. June 28, 2
2016-06-28
Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
App 20160137667 - BARTBERGER; Michael D. ;   et al.
2016-05-19
Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer
Grant 9,296,736 - Bartberger , et al. March 29, 2
2016-03-29
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
Grant 8,980,903 - Connors , et al. March 17, 2
2015-03-17
Fused Pyridine, Pyrimidine And Triazine Compounds As Cell Cycle Inhibitors
App 20140350244 - Connors; Richard V. ;   et al.
2014-11-27
Piperidinone Derivatives As Mdm2 Inhibitors For The Treatment Of Cancer
App 20140315895 - Bartberger; Michael D. ;   et al.
2014-10-23
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
Grant 8,841,312 - Connors , et al. September 23, 2
2014-09-23
Heterocyclic Compounds As Mdm2 Inhibitors For The Treatment Of Cancer
App 20140235629 - Bartberger; Michael D. ;   et al.
2014-08-21
Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
Grant 8,389,533 - Connors , et al. March 5, 2
2013-03-05
Piperidinone Derivatives As Mdm2 Inhibitors For The Treatment Of Cancer
App 20110319378 - BARTBERGER; Michael David ;   et al.
2011-12-29
Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors
App 20110142796 - Connors; Richard V. ;   et al.
2011-06-16
Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors
App 20110097305 - Connors; Richard V. ;   et al.
2011-04-28

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed